Recours à la biothérapie dans la prise en charge de la maladie de Behçet dans un service de médecine interne

[1]  L. Biard,et al.  Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet's disease: A multicenter observational study of 18 patients. , 2018, Clinical immunology.

[2]  C. Chiquet,et al.  [Therapeutic strategy for the treatment of non-infectious uveitis proposed by an expert panel]. , 2018, La Revue de medecine interne.

[3]  D. Kastner,et al.  A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease , 2018, Annals of the rheumatic diseases.

[4]  G. Hatemi,et al.  One year in review 2017: Behçet's syndrome. , 2017, Clinical and experimental rheumatology.

[5]  M. Resche-Rigon,et al.  Ustekinumab for Behçet's disease. , 2017, Journal of autoimmunity.

[6]  R. Barry,et al.  An update on the use of biologic therapies in the management of uveitis in Behçet’s disease: a comprehensive review , 2017, Orphanet Journal of Rare Diseases.

[7]  X. Mariette,et al.  Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. , 2015, Journal of autoimmunity.

[8]  P. Bielefeld,et al.  Uvéites et biothérapies , 2015 .

[9]  R. V. Van Gelder,et al.  Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. , 2014, Ophthalmology.

[10]  D. Saadoun,et al.  [Ocular manifestations in Behçet's disease]. , 2014, La Revue de medecine interne.

[11]  M. H. Houman,et al.  [Pathophysiology of Behçet's disease]. , 2014, La Revue de medecine interne.

[12]  D. Saadoun,et al.  Traitement de la maladie de Behçet , 2014 .

[13]  Z. Bahloul,et al.  Étude d’association des antigènes HLA classe I avec la maladie de Behçet dans le Sud tunisien , 2012 .

[14]  M. Frigui,et al.  [Association of HLA class I antigens with Behçet disease in South Tunisia]. , 2012, Pathologie-biologie.

[15]  P. Sfikakis,et al.  Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. , 2011, Seminars in arthritis and rheumatism.

[16]  D. Saadoun,et al.  Manifestations oculaires de la maladie de Behçet , 2010 .

[17]  M. Mochizuki,et al.  Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease , 2009, British Journal of Ophthalmology.

[18]  K. Tabbara,et al.  Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. , 2008, American journal of ophthalmology.

[19]  S. Ohno,et al.  Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. , 2007, Rheumatology.

[20]  I. Olivieri,et al.  New approaches in the treatment of Adamantiades-Behçet's disease , 2006, Current opinion in rheumatology.

[21]  P. Cacoub,et al.  [Ocular manifestations in Behçet's disease]. , 2018, La Revue de medecine interne.